Pfizer Inc. (NYSE: PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

The US stock market bounced back on Tuesday after the truce between Iran and Israel. The Dow Jones, Nasdaq 100, and S&P 500 indices jumped by over 1%, and the bullish momentum continued in the futures ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

Pfizer 's (PFE 0.30%) management team is confident in its 2025 opportunities. *Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Our detailed analysis of Pfizer’s upside post-inflation shock captures trends in the company’s stock during the turbulent market conditions seen over 2022.

Pfizer Inc. (NYSE: PFE), a global biopharmaceutical giant with a market capitalization of $139.52 billion, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...